Gene copy number variation (CNV) detection is a critical molecular testing service that identifies deletions, duplications, and amplifications of genomic DNA segments associated with genetic diseases, cancers, and transgenic organisms. Accredited third-party laboratories employ validated technologies such as qPCR, digital PCR, MLPA, array CGH, and next-generation sequencing (NGS) to deliver accurate, standards-compliant CNV analysis for clinical, research, and biopharmaceutical applications.
Technical Overview
Copy number variations (CNVs) are structural genomic alterations defined as deletions or duplications of DNA segments, typically ranging from 1 kilobase to several megabases in size. CNVs are among the most significant sources of human genetic diversity, but pathogenic CNVs are also responsible for a substantial proportion of developmental disorders, intellectual disability, congenital anomalies, and neuropsychiatric conditions. In oncology, gene amplifications and deletions serve as diagnostic biomarkers, prognostic indicators, and predictive markers for targeted therapy selection.
Gene CNV detection quantifies the dosage of specific genomic regions relative to a reference state (usually diploid). Depending on the technology deployed, assays can resolve single-exon deletions in large genes, whole-chromosome aneuploidies, and genome-wide submicroscopic imbalances. Modern CNV testing workflows incorporate rigorous quality management aligned with ISO 15189 (medical laboratory quality and competence), ISO/IEC 17025 (general testing laboratory competence), and relevant CLSI and GB/T molecular diagnostic guidelines. Laboratories performing CNV detection typically implement validated wet-lab protocols, calibrated instrumentation, reference materials or internal controls, and bioinformatics pipelines with documented analytical sensitivity, specificity, and precision.
Testing Samples
Human Peripheral Blood and Germline Specimens
Ethylenediaminetetraacetic acid (EDTA) anticoagulated peripheral blood is the standard germline sample for constitutional CNV analysis. Buccal swabs and saliva-derived genomic DNA are acceptable non-invasive alternatives when blood collection is impractical. Germline specimens are used for detecting inherited or de novo CNVs associated with monogenic disorders.
Tumor Tissue and FFPE Specimens
Fresh-frozen tumor tissue and formalin-fixed paraffin-embedded (FFPE) blocks are used for somatic CNV profiling in oncology. FFPE-derived DNA is often fragmented; therefore, assays intended for FFPE material must be validated for degraded and low-input DNA. Matched normal tissue may be analyzed in parallel to distinguish germline from somatic events.
Prenatal and Preimplantation Specimens
Chorionic villus samples, amniotic fluid, and cultured amniocytes support invasive prenatal CNV diagnosis, while cell-free fetal DNA isolated from maternal plasma enables non-invasive prenatal screening for common aneuploidies and selected microdeletion syndromes. Trophectoderm biopsy specimens can be evaluated in preimplantation genetic testing contexts.
Cell Lines, Biopharmaceutical Products, and Microbial Strains
Cell bank DNA, viral vector preparations, and engineered microbial or production cell lines are tested to determine transgene or vector copy number, confirm clonality, and support product characterization in accordance with quality system requirements such as ISO 13485 where applicable.
Plant and Agricultural Specimens
Young leaves, seeds, embryos, and processed plant materials are accepted for transgene copy number determination in genetically modified (GM) event characterization, hybrid purity assessment, and marker-assisted breeding programs.
Testing Items
CNV detection portfolios typically encompass the following categories of testing items:
- Single-gene CNV analysis: dosage evaluation of disease genes with high CNV burden, including SMN1/SMN2 (spinal muscular atrophy), DMD (Duchenne/Becker muscular dystrophy), PMP22 (Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies), PLP1, and CYP2D6 (pharmacogenomic copy number).
- Oncology gene panel CNV analysis: amplification and deletion status of ERBB2 (HER2), EGFR, MET, MYC, CCND1, MDM2, CDK4, FGFR1, FGFR2, PIK3CA, and deletions of PTEN, CDKN2A/B, RB1, and BRCA1/2.
- Chromosomal aneuploidy detection: copy number assessment of chromosomes 13, 18, 21, X, and Y, plus rare aneuploidies across the genome.
- Microdeletion and microduplication syndromes: targeted or genome-wide detection of recurrent syndromic regions including 22q11.2 deletion/duplication, 15q11-q13 (Prader-Willi/Angelman), 1p36 deletion, 7q11.23 (Williams), 17p11.2 (Smith-Magenis), 5p (Cri-du-chat), and 16p11.2.
- Genome-wide CNV profiling: high-resolution screening of all chromosomes for pathogenic copy number changes meeting clinical reporting size thresholds.
- Transgene and vector copy number: quantification of inserted gene copies in GM plants, gene-edited organisms, recombinant production cell lines, and gene therapy vectors.
- Companion CNV confirmation: orthogonal verification of candidate CNVs identified by sequencing-based screening, using an independent method such as MLPA, qPCR, or digital PCR.
Testing Methods
Quantitative Real-Time PCR (qPCR)
qPCR determines relative or absolute copy number by comparing amplification kinetics of a target locus against a reference gene known to be diploid. The delta-delta Ct (ΔΔCt) method normalizes target amplification across sample and calibrator DNA, providing rapid, economical single-locus dosage assessment with turnaround times of hours. Assay design must account for reference gene stability, PCR efficiency equivalence, and sequence uniqueness to avoid pseudogene interference.
Droplet Digital PCR (dPCR)
Digital PCR partitions reactions into thousands of individual droplets or wells and applies Poisson statistics to endpoint fluorescence counts, yielding absolute copy number quantification without external calibrators. dPCR delivers superior precision for low-fold copy number changes (for example, distinguishing two from three copies) and is particularly suited to copy number determination of transgenes, vectors, and clinically relevant loci such as CYP2D6.
Multiplex Ligation-Dependent Probe Amplification (MLPA)
MLPA uses a probe set of up to dozens of locus-specific oligonucleotide pairs that hybridize to genomic DNA, ligate, and amplify with universal primers. Relative peak areas reveal copy number at every probed exon, enabling exon-level deletion/duplication scanning across large genes such as DMD and SMN1 in a single reaction. MLPA is widely regarded as a first-line constitutional CNV assay in clinical diagnostics.
Array-Based Cytogenomics (Array CGH and SNP Array)
Array comparative genomic hybridization (aCGH) co-hybridizes differentially labeled sample and reference DNA onto oligonucleotide or BAC probes immobilized on a slide, detecting unbalanced genome-wide CNVs at kilobase resolution. SNP arrays additionally interrogate single nucleotide polymorphisms, permitting detection of copy-neutral loss of heterozygosity, triploidy, and regions of absence of heterozygosity. Array platforms remain a mainstay for postnatal developmental delay and congenital anomaly workups.
Next-Generation Sequencing (NGS)
NGS-based CNV calling infers dosage from read-depth signatures across whole-genome sequencing (WGS), whole-exome sequencing (WES), or targeted hybrid-capture panels. Advanced pipelines integrate read-depth, read-pair orientation, and split-read evidence to resolve deletions, duplications, and partial amplifications. Sequencing panels that simultaneously detect single nucleotide variants, insertions/deletions, and CNVs from one specimen offer efficient comprehensive genomic profiling, particularly in oncology.
Fluorescence In Situ Hybridization (FISH)
FISH employs locus-specific fluorescent probes hybridized to interphase nuclei or metaphase chromosomes to visualize copy number and genomic position. While lower in throughput, FISH is valuable for confirming amplifications such as ERBB2 (HER2), assessing structural complexity, and analyzing samples with limited DNA yield or heterogeneous tumors.
Method Selection and Validation
Method choice depends on genomic scope, resolution requirements, sample type, and clinical context. Accredited third-party laboratories validate each assay for accuracy, precision, limit of detection, reportable range, and robustness using reference materials, blinded replica comparisons, and orthogonal method confirmation. Bioinformatics CNV pipelines are locked under change control, and reported results are interpreted according to professional college classification frameworks (such as ACMG criteria for constitutional CNVs) with documented variant nomenclature following ISCN or HGVS conventions.
Applications
- Clinical genetics and rare disease diagnosis: identification of pathogenic CNVs in patients with developmental delay, intellectual disability, multiple congenital anomalies, autism spectrum disorders, and epilepsy, enabling definitive diagnosis, recurrence risk counseling, and family cascade testing.
- Prenatal and preimplantation genetics: diagnosis of aneuploidies and clinically significant microdeletion/microduplication syndromes from invasive specimens and screening via cell-free DNA analysis.
- Oncology and precision medicine: HER2 amplification testing for breast and gastroesophageal cancer management, MET and EGFR amplification assessment, PTEN and CDKN2A deletion profiling, and comprehensive genomic profiling to guide targeted therapy and clinical trial enrollment.
- Pharmacogenomics: CYP2D6 and related gene copy number determination to individualize drug dosing for medications metabolized by copy-number-sensitive enzymes.
- Agricultural biotechnology and seed quality: transgene copy number quantification for GM event selection, insertion characterization, hybrid purity verification, and compliance testing against regulatory thresholds.
- Biopharmaceutical quality control: vector copy number in gene therapy products, producer cell line stability studies, and cell bank characterization supporting regulatory submissions.
- Research and development: CNV discovery in population genetics, model organism phenotyping, and genotype-phenotype correlation studies.
FAQ
What sample quantity and quality are required for CNV detection?
Typical requirements are 50-200 ng of high-quality genomic DNA with adequate purity ratios (A260/A280 of approximately 1.8), although validated protocols for FFPE or low-input specimens may accept fragmented DNA down to tens of nanograms. Exact input thresholds vary by platform and should be confirmed with the testing laboratory before submission.
What resolution and size limits can CNV testing achieve?
Resolution depends on methodology: qPCR and dPCR interrogate predefined loci and can distinguish single-copy differences; MLPA resolves single-exon changes within targeted genes; SNP arrays typically detect events from approximately 50-100 kb genome-wide; and WGS-based analysis can approach breakpoint-level resolution depending on sequencing depth. Assays should be matched to the clinical or regulatory question being asked.
Can CNV detection identify point mutations or balanced rearrangements?
No. CNV assays detect changes in DNA dosage. Single nucleotide variants and small insertions/deletions require sequencing, while balanced translocations and inversions require karyotyping, FISH, or specialized sequencing analysis. Combined NGS panels are available when simultaneous detection of sequence variants and CNVs is needed.
What is the typical turnaround time?
Single-locus qPCR or dPCR assays are often completed within 3-7 working days; MLPA testing generally requires 7-10 working days; array-based and NGS genome-wide analyses typically require 10-20 working days depending on complexity, confirmation studies, and reporting requirements.
How is result quality assured?
Reputable providers operate under ISO 15189 or ISO/IEC 17025 quality systems with validated assays, calibrated equipment, documented competency records, participation in proficiency testing schemes, and internal quality controls in every run. Findings of clinical significance are routinely confirmed with an orthogonal method before reporting.
How are CNV results classified and reported?
Constitutional CNVs are classified into pathogenic, likely pathogenic, uncertain significance, likely benign, and benign categories according to professional college (ACMG) technical standards, incorporating evidence from curated databases, medical literature, inheritance pattern, and predicted gene dosage sensitivity. Reports include genomic coordinates (genome build), method, reference standards, and recommended clinical follow-up or family studies where appropriate.